Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977910 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
J Adv Pract Oncol
July 2024
New York Oncology Hematology, Albany, New York.
Introduction: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium™ (MYLUNG) clinical trial platform aims to advance the use of precision medicine in patients with non-small cell lung cancer through a series of prospective and iterative clinical trials. Timely patient accrual onto oncology clinical trials is a known practice challenge and impaired accrual rates can lead to premature trial closure or properly powered trial outcomes. The US Oncology Network recently implemented a clinical pharmacist (ClinReview) initiative to provide remote clinical services to screen patients for enrollment onto MYLUNG Protocol 2.
View Article and Find Full Text PDFEnhancement of Air-Entrained Grout-Enriched Vibrated Cemented Sand, Gravel and Rock (GECSGR) for Improving Frost and Thawing Resistance in CSGR Dams.
Materials (Basel)
January 2025
School of Civil Engineering, Beijing Jiaotong University, Beijing 100044, China.
Cemented Sand, Gravel, and Rock (CSGR) dams have traditionally used either Conventional Vibrated Concrete (CVC) or Grout-Enriched Roller Compacted Concrete (GERCC) for protective and seepage control layers in low- to medium-height dams. However, these methods are complex, prone to interference, and uneconomical due to significant differences in the expansion coefficient, elastic modulus, and hydration heat parameters among CSGR, CVC, and GERCC. This complexity complicates quality control during construction, leading to the development of Grout-Enriched Vibrated Cemented Sand, Gravel, and Rock (GECSGR) as an alternative.
View Article and Find Full Text PDFKrebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis.
J Immunother Cancer
December 2024
Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan
Background: The immune-related adverse event (irAE), pneumonitis, is a potentially fatal complication of immune checkpoint inhibitors (ICIs). Preventing its progression is crucial, emphasizing the need for effective screening tests. We evaluated the feasibility of using Krebs von den Lungen-6 (KL-6), a marker for interstitial pneumonitis, as a screening tool for pneumonitis.
View Article and Find Full Text PDFSimvastatin is delivered to the brain by high-strength intranasal cationic SMEDDS and nanoemulsions.
Drug Deliv Transl Res
January 2025
Faculty of Health Sciences (FCS), University of Beira Interior, Av. Infante D. Henrique, Covilhã, 6200-506, Portugal.
The repurposing of statins as neuroprotective agents and/or anti-brain tumor drugs is limited by challenges in brain bioavailability and systemic off-target effects. Therefore, improved and targeted delivery of statins to the brain is necessary. This study aimed to develop a high-strength liquid formulation of the poorly soluble prodrug simvastatin for intranasal administration, as a strategy to achieve high brain concentrations of the prodrug and/or its active form, tenivastatin.
View Article and Find Full Text PDFEpidemiology of late-onset sepsis in Malaysian neonatal intensive care units, 2015-2020.
Malays J Pathol
December 2024
Tengku Ampuan Rahimah Hospital, Department of Paediatrics, Ministry of Health, Klang, Selangor, Malaysia.
Introduction: To determine the epidemiology of blood culture-positive late-onset sepsis (LOS, >72 hours of age) in 44 Malaysian neonatal intensive care units (NICUs).
Materials And Methods: Study Design: Multicentre retrospective observational study using data from the Malaysian National Neonatal Registry.
Participants: 739486 neonates (birthweight ≥500g, gestation ≥22 weeks) born and admitted in 2015-2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!